MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

50.057

88.032

EPS

0.4

Dividendrendement

0.29

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+14.96% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.26%

Volgende Winsten

30 jan 2026

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.8M

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

40%

60%

114 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jan 2026, 22:45 UTC

Belangrijke Marktbewegers

GH Research Shares Up, Plans to Provide Update on New Drug Application

2 jan 2026, 22:13 UTC

Marktinformatie
Winsten

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

2 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 jan 2026, 21:07 UTC

Winsten

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2 jan 2026, 20:09 UTC

Marktinformatie

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2 jan 2026, 19:48 UTC

Marktinformatie

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2 jan 2026, 18:53 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 jan 2026, 18:53 UTC

Marktinformatie

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2 jan 2026, 17:56 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2 jan 2026, 17:50 UTC

Marktinformatie

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2 jan 2026, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 jan 2026, 16:33 UTC

Marktinformatie

Remittances to Mexico Fell 5.7% in November -- Market Talk

2 jan 2026, 16:18 UTC

Marktinformatie

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2 jan 2026, 15:48 UTC

Winsten

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2 jan 2026, 15:17 UTC

Marktinformatie

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2 jan 2026, 15:01 UTC

Marktinformatie

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2 jan 2026, 15:00 UTC

Winsten

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2 jan 2026, 14:56 UTC

Marktinformatie

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2 jan 2026, 14:20 UTC

Marktinformatie

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2 jan 2026, 14:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 jan 2026, 14:13 UTC

Marktinformatie

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2 jan 2026, 13:39 UTC

Marktinformatie

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2 jan 2026, 13:01 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2 jan 2026, 12:45 UTC

Marktinformatie

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2 jan 2026, 11:48 UTC

Marktinformatie

European Gas Climbs as Cold Weather Bites -- Market Talk

2 jan 2026, 11:36 UTC

Marktinformatie

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2 jan 2026, 11:30 UTC

Marktinformatie

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2 jan 2026, 11:29 UTC

Marktinformatie

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2 jan 2026, 11:15 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

14.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.22Ā USDĀ  14.96%

Hoogste 123Ā USD

Laagste 100Ā USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

114 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat